Innovation at the point-of-care

Lumos develops, manufactures and distributes world-leading diagnostic technologies - delivering actionable information, in real time, at the point-of-care.

Welcome to Lumos

World-class point-of-care products

Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately assess, diagnose and manage medical conditions.

FebriDx®

Rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial infection and non-bacterial etiology.

ViraDx

Rapid point-of-care test that simultaneously tests for acute respiratory infections caused by the COVID-19, Influenza A and Influenza B viruses.

Lumos Development & Contract Manufacturing Services

Lumos specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. We offer customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.

How Lumos can help your business

Strategic Innovation

Initial evaluation of a point-of-care diagnostic test product concept and the development of new diagnostic test assay.

Development and Manufacturing Transfer

Development of new point-of-care diagnostic test products, including use of Lumos technology platform and the customization and integration of Lumos digital reader technology when requested by Lumos clients.

Validation and Commercial Manufacturing

Clinical and product validation and commercial-scale manufacture of test strips and readers.

Medical, Quality and Regulatory Affairs

In house, qualified team to support all stages of product development and commercialization.

FebriDx featured on Channel 9 News, Australia

Learn more about the Australian roll-out of FebriDx

This device is now available via qualified clinicians to help patients more accurately navigate the need for antibiotics.

Lumos News

Lumos Diagnostics Signs Second ANZ Distribution Agreement for FebriDx®
9 September 2025

Lumos Diagnostics has signed a new distribution agreement with Amtech, part of the YesGroup alliance

Lumos FY25 Results Investor Briefing
3 September 2025

During this briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, Senior VP Commercial Operations, Paul Kase, and VP Medical Affairs, Annie Bell provide an overview of the FY25 results and a general business update.

Lumos secures follow-on contract with Aptatek Biosciences for development of PKU in-home monitoring device
1 September 2025

Lumos has secured a follow-on contract with Aptatek Biosciences to advance the PheCheck™ in-home monitoring device for phenylketonuria (PKU).

Subscribe for Lumos news and investor updates

By entering your email address you are agreeing to our Privacy Policy.